ASRS 2023: 27-Gauge vs 25-gauge vitrectomy for symptomatic vitreous opacities
August 2nd 2023Our team spoke with Shawn Kavoussi, MD, at the 2023 ASRS meeting in Seattle, Washington about his research on using infrared video for vitreous opacities and comparing postoperative reduction in vitreous opacity scores using infrared video with the Heidelberg spectralis unit.
ASRS 2023: Michael Ip, MD, on key trends and perspectives from the 2023 meeting in Seattle
August 1st 2023Michael Ip, MD, spoke with our team at the 2023 ASRS meeting in Seattle, Washington. He noted presentations and trends that are key at this event and why they're vital to a modern view of ophthalmology.
ASRS 2023: Sharing outcomes and clinical features predictive of fungal endophthalmitis
July 29th 2023Mark Breazzano, MD, FACS, who is presenting Outcomes and Clinical Features Predictive of Fungal Endophthalmitis at the 2023 ASRS meeting in Seattle, Washington spoke with our team about this research.
BREAKING NEWS: FDA approves XDEMVY for treatment of Demodex blepharitis
July 25th 2023According to Tarsus Pharmaceuticals, lotilaner ophthalmic solution 0.25% (XDEMVY) is the first approved therapeutic for Demodex blepharitis, and has demonstrated efficacy across multiple clinical measures of disease.
Breaking News: FDA approves perfluorohexyloctane ophthalmic solution for dry eye disease
May 18th 2023According to Bausch + Lomb and Novaliq, MIEBO is the first prescription eye drop approved for dry eye disease that directly targets tear evaporation, based on consistent results from a pair of pivotal Phase 3 trials.
COPHy 2023: Presence of macular neovascularisation on OCTA is predictive of subsequent exudation
March 24th 2023Angela Carneiro, MD, PhD, discusses her position on a discussion titled Presence of Macular Neovascularization on OCTA is Predictive of Subsequent Exudation with David Hutton, Executive Editor, Ophthalmology Times®.